Aggregation, stability, and formulation of human antibody therapeutics

D Lowe, K Dudgeon, R Rouet, P Schofield… - Advances in protein …, 2011 - Elsevier
Many human monoclonal antibodies display poor biophysical properties, such as low
stability and a propensity to aggregate. These unfavorable tendencies can be even more …
被引用次数：203 相关文章

Aggregation, stability, and formulation of human antibody therapeutics

D Lowe, K Dudgeon, R Rouet… - Advances in …, 2011 - pubmed.ncbi.nlm.nih.gov
Many human monoclonal antibodies display poor biophysical properties, such as low
stability and a propensity to aggregate. These unfavorable tendencies can be even more …
[PDF] academia.edu

[PDF][PDF] AGGREGATION, STABILITY, AND FORMULATION OF HUMAN ANTIBODY THERAPEUTICS

D LOWE, K DUDGEON, R ROUET, P SCHOFIELD - academia.edu
Many human monoclonal antibodies display poor biophysical properties, such as low
stability and a propensity to aggregate. These unfavorable tendencies can be even more …

[引用][C] Aggregation, stability, and formulation of human antibody therapeutics

D Lowe, K Dudgeon, R Rouet, P Schofield… - Advances in Protein …, 2011 - cir.nii.ac.jp

Aggregation, stability, and formulation of human antibody therapeutics.

D Lowe, K Dudgeon, R Rouet, P Schofield… - Advances in Protein …, 2011 - europepmc.org
Many human monoclonal antibodies display poor biophysical properties, such as low
stability and a propensity to aggregate. These unfavorable tendencies can be even more …

AGGREGATION, STABILITY, AND FORMULATION OF HUMAN ANTIBODY THERAPEUTICS

D LOWE, K DUDGEON, R ROUET… - Advances in Protein …, 2011 - books.google.com
Many human monoclonal antibodies display poor biophysical properties, such as low
stability and a propensity to aggregate. These unfavorable tendencies can be even more …